KA/EN
Register
Medicines reference
Search
Search
Active substance

Nitrofurantoin

Favourites

Nitrofuran. No registration in force in Georgia. Forms: tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Nitrofurantoin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
4.4 mg/kg
off-label
 Dog, Cat Urinary Tract Infection By mouth 3 times daily
MSD Vet Manual 2025
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Nitrofurans Use in Animals
MSD/Merck Veterinary Manual, 2025
Before use

Safety information

Known Contraindications

  • Critical
    Avoid with impaired renal function or inadequate urine production: urinary efficacy can decrease while systemic accumulation and polyneuritis risk increase.
    Sources: MSD Vet Manual
  • Warning
    Use caution in very young animals; yellow tooth discolouration has occasionally been reported and safety is not adequately established.
    Sources: MSD Vet Manual
Latin name
Nitrofurantoin
Georgian name
ნიტროფურანტოინი
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
0 of 2 forms
Products
Furadonin
Human medicines in Georgia
Magromag
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Furadonin 50 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Culture-confirmed susceptible lower bacterial cystitis when preferred veterinary-authorised antimicrobials are unsuitable; never pyelonephritis, prostatitis or systemic infection
5.2/10
Weak evidence support
vetman assessment

Furadonin

50 mg, tablet, human medicine
Assessed clinical scopeDog · Culture-confirmed susceptible lower bacterial cystitis when preferred veterinary-authorised antimicrobials are unsuitable; never pyelonephritis, prostatitis or systemic infection · By mouth
Care settingVeterinarian-directed home treatment after urinalysis and culture, with exact-weight dosing every 8 hours, renal review and early clinical reassessment.
vetman score 5.2/10 Weak evidence support
Evidence confidence: Medium Georgia: Discontinued · № რ-042450 · Verified on 22 Oct 2026 Off-label use

A culture-directed reserve urinary drug with plausible canine efficacy but meaningful safety, adherence and exact-tablet dose-unit limitations. Use only for susceptible lower cystitis after better-characterised veterinary options are unsuitable, never for renal-tissue or prostatic infection.

Regulatory and scientific credibility4.5/10

The exact Irbit 50 mg plain tablet has identifiable official manufacturer information and a current Georgian registration entry, but another catalogue evidence row says that certificate is suspended for absent GMP documentation. Exact EU/EEA, GB and US entries were not found, and animal use is off-label.

Clinical efficacy6.5/10

ISCAID reserves 4.4-5 mg/kg every 8 hours for susceptible sporadic cystitis, especially multidrug-resistant infections. A controlled canine urine study found the q8h regimen produced urinary concentrations above relevant isolate MICs, and small clinical series support a role, but robust comparative cure trials and exact-Furadonin veterinary outcomes are absent.

Safety and tolerability5.0/10

Short q8h canine courses were generally tolerated in recent studies, but gastrointestinal effects, hypersensitivity, hepatic or pulmonary injury and potentially serious polyneuropathy remain relevant. Renal impairment both lowers urinary efficacy and increases systemic accumulation; exact-product canine safety and reproductive data are absent.

Clinical practicality4.5/10

At 4.4-5 mg/kg, one intact 50 mg tablet fits only about a 10-11.4 kg dog per dose. It is more usable than the 100 mg strength but remains a plain tablet without validated equal division or crushing, and every-8-hour dosing with food and water is burdensome.

Full-course cost-effectiveness-

Current comparable full-course local prices were not verified.

Important safety and use flags

  • Confirm bacterial cystitis before treatment. Culture and susceptibility are required in cats and strongly preferred in dogs; most feline lower urinary signs are not bacterial, and asymptomatic bacteriuria usually should not be treated.
  • Reserve nitrofurantoin for a susceptible lower urinary isolate when preferred veterinary-authorised options are unsuitable. Do not use it as routine empirical therapy or merely because a urine dipstick is abnormal.
  • LOWER URINARY TRACT ONLY. Do not use for pyelonephritis, prostatitis, fever/systemic infection or another tissue infection: therapeutic concentrations are achieved in urine, not renal parenchyma, prostate, blood or other tissues.
  • Do not use with impaired renal function or inadequate urine production. Reduced excretion can lower urinary efficacy while increasing systemic accumulation and polyneuropathy risk; assess creatinine, hydration and urine output before dosing.
  • Stop promptly and reassess for weakness, crouched gait, reduced reflexes, ataxia, tremor, confusion or another neurologic change. Peripheral polyneuropathy can be serious and has been reported in a cat at a conventional q8h regimen.
  • Give with food and water and monitor for nausea, vomiting, diarrhoea or anorexia. Stop and investigate persistent gastrointestinal signs, jaundice/hepatopathy, respiratory signs, fever, rash, facial swelling or another hypersensitivity reaction.
  • Safety in pregnancy, lactation, breeding animals and very young patients is not adequately established for these exact human presentations. Do not assume human paediatric use proves veterinary reproductive or neonatal safety.
  • Review the complete medication list. Antacids containing magnesium, urinary alkalinisers and agents that inhibit tubular secretion can reduce urinary activity or increase toxicity; avoid unreviewed combination with fluoroquinolones because antagonism is described in exact human instructions.
  • Dose from exact body weight and the prescribed 4.4-5 mg/kg every-8-hour regimen; do not substitute a once-daily prophylaxis protocol for active infection. Missed q8h doses and poor adherence can materially compromise this short-half-life urinary drug.
  • Use only a validated dose unit. These exact 50 mg and 100 mg plain tablets have no documented equal-dose score or validated crushing/powder-division method; do not estimate small fractions by eye. Use an appropriate strength or compounded preparation when the intact tablet cannot match the calculated dose.
Assessment sources
  1. VVKT Furadonins 100 mg2024
  2. Olainfarm Furadonin 100 mg2026
  3. Irbit Furadonin 50 mg2026
  4. Georgia Furadonin register2026
  5. ISCAID urinary guideline 20192019
  6. MSD Vet Manual 20252025
  7. Canine q8h urine study2023
  8. Canine recurrent-UTI series2023
  9. Canine/feline isolate study2011
  10. Feline polyneuropathy case2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Culture-confirmed susceptible lower bacterial cystitis when preferred veterinary-authorised antimicrobials are unsuitable; never pyelonephritis, prostatitis or systemic infection
3.9/10
Poor / unconvincing
vetman assessment

Furadonin

50 mg, tablet, human medicine
Assessed clinical scopeCat · Culture-confirmed susceptible lower bacterial cystitis when preferred veterinary-authorised antimicrobials are unsuitable; never pyelonephritis, prostatitis or systemic infection · By mouth
Care settingVeterinarian-directed home treatment after urinalysis and culture, with exact-weight dosing every 8 hours, renal review and early clinical reassessment.
vetman score 3.9/10 Poor / unconvincing
Evidence confidence: Low Georgia: Discontinued · № რ-042450 · Verified on 22 Oct 2026 Off-label use

A weak-to-poor feline reserve presentation. Consensus and isolate data suggest urinary activity, but direct feline efficacy is sparse, polyneuropathy has now been reported, renal function is critical and these 50/100 mg whole-tablet units cannot deliver a typical cat dose accurately.

Regulatory and scientific credibility4.5/10

The exact Irbit 50 mg plain tablet has identifiable official manufacturer information and a current Georgian registration entry, but another catalogue evidence row says that certificate is suspended for absent GMP documentation. Exact EU/EEA, GB and US entries were not found, and animal use is off-label.

Clinical efficacy4.5/10

ISCAID includes the same 4.4-5 mg/kg every-8-hour reserve regimen for dogs and cats, and canine/feline isolate MICs support potential urinary activity. Direct feline PK and controlled clinical-outcome evidence are essentially absent, bacterial cystitis is uncommon in younger cats and this exact human tablet has no feline formulation evidence.

Safety and tolerability3.5/10

A 2025 cat developed presumptive peripheral polyneuropathy after 4 mg/kg every 8 hours, improving after withdrawal; the case also had impaired renal indicators. Alongside gastrointestinal, hepatic, pulmonary and hypersensitivity risks, sparse feline safety data and renal dependence make the margin materially uncertain.

Clinical practicality2.5/10

A typical 4 kg cat requires about 17.6-20 mg per dose, still well below one 50 mg tablet. The exact plain tablet has no validated equal subdivision or crushing method; although less mismatched than 100 mg, accurate every-8-hour home dosing generally requires an appropriate compounded or alternative presentation.

Full-course cost-effectiveness-

Current comparable full-course local prices were not verified.

Important safety and use flags

  • Confirm bacterial cystitis before treatment. Culture and susceptibility are required in cats and strongly preferred in dogs; most feline lower urinary signs are not bacterial, and asymptomatic bacteriuria usually should not be treated.
  • Reserve nitrofurantoin for a susceptible lower urinary isolate when preferred veterinary-authorised options are unsuitable. Do not use it as routine empirical therapy or merely because a urine dipstick is abnormal.
  • LOWER URINARY TRACT ONLY. Do not use for pyelonephritis, prostatitis, fever/systemic infection or another tissue infection: therapeutic concentrations are achieved in urine, not renal parenchyma, prostate, blood or other tissues.
  • Do not use with impaired renal function or inadequate urine production. Reduced excretion can lower urinary efficacy while increasing systemic accumulation and polyneuropathy risk; assess creatinine, hydration and urine output before dosing.
  • Stop promptly and reassess for weakness, crouched gait, reduced reflexes, ataxia, tremor, confusion or another neurologic change. Peripheral polyneuropathy can be serious and has been reported in a cat at a conventional q8h regimen.
  • Give with food and water and monitor for nausea, vomiting, diarrhoea or anorexia. Stop and investigate persistent gastrointestinal signs, jaundice/hepatopathy, respiratory signs, fever, rash, facial swelling or another hypersensitivity reaction.
  • Safety in pregnancy, lactation, breeding animals and very young patients is not adequately established for these exact human presentations. Do not assume human paediatric use proves veterinary reproductive or neonatal safety.
  • Review the complete medication list. Antacids containing magnesium, urinary alkalinisers and agents that inhibit tubular secretion can reduce urinary activity or increase toxicity; avoid unreviewed combination with fluoroquinolones because antagonism is described in exact human instructions.
  • Dose from exact body weight and the prescribed 4.4-5 mg/kg every-8-hour regimen; do not substitute a once-daily prophylaxis protocol for active infection. Missed q8h doses and poor adherence can materially compromise this short-half-life urinary drug.
  • Use only a validated dose unit. These exact 50 mg and 100 mg plain tablets have no documented equal-dose score or validated crushing/powder-division method; do not estimate small fractions by eye. Use an appropriate strength or compounded preparation when the intact tablet cannot match the calculated dose.
Assessment sources
  1. VVKT Furadonins 100 mg2024
  2. Olainfarm Furadonin 100 mg2026
  3. Irbit Furadonin 50 mg2026
  4. Georgia Furadonin register2026
  5. ISCAID urinary guideline 20192019
  6. MSD Vet Manual 20252025
  7. Canine q8h urine study2023
  8. Canine recurrent-UTI series2023
  9. Canine/feline isolate study2011
  10. Feline polyneuropathy case2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Nitrofurantoin50 mg
Formulation Type
Tablet
Administration route
By mouth
Registration
Georgia Discontinued
Human (Ministry of Health, RAMA)
In the register: ფურადონინი 50 მგ, ტაბლეტი
№ რ-042450
Verified on: 22 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Furadonin 100 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Culture-confirmed susceptible lower bacterial cystitis when preferred veterinary-authorised antimicrobials are unsuitable; never pyelonephritis, prostatitis or systemic infection
5.6/10
Weak evidence support
vetman assessment

Furadonin

100 mg, tablet, human medicine
Assessed clinical scopeDog · Culture-confirmed susceptible lower bacterial cystitis when preferred veterinary-authorised antimicrobials are unsuitable; never pyelonephritis, prostatitis or systemic infection · By mouth
Care settingVeterinarian-directed home treatment after urinalysis and culture, with exact-weight dosing every 8 hours, renal review and early clinical reassessment.
vetman score 5.6/10 Weak evidence support
Evidence confidence: Medium Georgia: Expired · № რ-033307 · Verified on 22 Oct 2026 Off-label use

A culture-directed reserve urinary drug with plausible canine efficacy but meaningful safety, adherence and exact-tablet dose-unit limitations. Use only for susceptible lower cystitis after better-characterised veterinary options are unsuitable, never for renal-tissue or prostatic infection.

Regulatory and scientific credibility6.5/10

This exact Olainfarm/Olpha 100 mg plain tablet has a current Lithuanian national authorisation, regulator-hosted 2024 product documents and current manufacturer information. It is a human presentation with no dog or cat authorisation; the catalogue market rows incorrectly report no EU/EEA registration and a current Georgian status despite an expired Georgian record.

Clinical efficacy6.5/10

ISCAID reserves 4.4-5 mg/kg every 8 hours for susceptible sporadic cystitis, especially multidrug-resistant infections. A controlled canine urine study found the q8h regimen produced urinary concentrations above relevant isolate MICs, and small clinical series support a role, but robust comparative cure trials and exact-Furadonin veterinary outcomes are absent.

Safety and tolerability5.0/10

Short q8h canine courses were generally tolerated in recent studies, but gastrointestinal effects, hypersensitivity, hepatic or pulmonary injury and potentially serious polyneuropathy remain relevant. Renal impairment both lowers urinary efficacy and increases systemic accumulation; exact-product canine safety and reproductive data are absent.

Clinical practicality3.5/10

At 4.4-5 mg/kg, one intact 100 mg tablet fits only about a 20-22.7 kg dog per dose. The exact tablet is plain and not documented for equal division or crushing; three daily doses with food and water impose substantial adherence burden and make most other weights impractical without a compounded or lower-strength alternative.

Full-course cost-effectiveness-

Current comparable full-course local prices were not verified.

Important safety and use flags

  • Confirm bacterial cystitis before treatment. Culture and susceptibility are required in cats and strongly preferred in dogs; most feline lower urinary signs are not bacterial, and asymptomatic bacteriuria usually should not be treated.
  • Reserve nitrofurantoin for a susceptible lower urinary isolate when preferred veterinary-authorised options are unsuitable. Do not use it as routine empirical therapy or merely because a urine dipstick is abnormal.
  • LOWER URINARY TRACT ONLY. Do not use for pyelonephritis, prostatitis, fever/systemic infection or another tissue infection: therapeutic concentrations are achieved in urine, not renal parenchyma, prostate, blood or other tissues.
  • Do not use with impaired renal function or inadequate urine production. Reduced excretion can lower urinary efficacy while increasing systemic accumulation and polyneuropathy risk; assess creatinine, hydration and urine output before dosing.
  • Stop promptly and reassess for weakness, crouched gait, reduced reflexes, ataxia, tremor, confusion or another neurologic change. Peripheral polyneuropathy can be serious and has been reported in a cat at a conventional q8h regimen.
  • Give with food and water and monitor for nausea, vomiting, diarrhoea or anorexia. Stop and investigate persistent gastrointestinal signs, jaundice/hepatopathy, respiratory signs, fever, rash, facial swelling or another hypersensitivity reaction.
  • Safety in pregnancy, lactation, breeding animals and very young patients is not adequately established for these exact human presentations. Do not assume human paediatric use proves veterinary reproductive or neonatal safety.
  • Review the complete medication list. Antacids containing magnesium, urinary alkalinisers and agents that inhibit tubular secretion can reduce urinary activity or increase toxicity; avoid unreviewed combination with fluoroquinolones because antagonism is described in exact human instructions.
  • Dose from exact body weight and the prescribed 4.4-5 mg/kg every-8-hour regimen; do not substitute a once-daily prophylaxis protocol for active infection. Missed q8h doses and poor adherence can materially compromise this short-half-life urinary drug.
  • Use only a validated dose unit. These exact 50 mg and 100 mg plain tablets have no documented equal-dose score or validated crushing/powder-division method; do not estimate small fractions by eye. Use an appropriate strength or compounded preparation when the intact tablet cannot match the calculated dose.
Assessment sources
  1. VVKT Furadonins 100 mg2024
  2. Olainfarm Furadonin 100 mg2026
  3. Irbit Furadonin 50 mg2026
  4. Georgia Furadonin register2026
  5. ISCAID urinary guideline 20192019
  6. MSD Vet Manual 20252025
  7. Canine q8h urine study2023
  8. Canine recurrent-UTI series2023
  9. Canine/feline isolate study2011
  10. Feline polyneuropathy case2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Culture-confirmed susceptible lower bacterial cystitis when preferred veterinary-authorised antimicrobials are unsuitable; never pyelonephritis, prostatitis or systemic infection
4.3/10
Weak evidence support
vetman assessment

Furadonin

100 mg, tablet, human medicine
Assessed clinical scopeCat · Culture-confirmed susceptible lower bacterial cystitis when preferred veterinary-authorised antimicrobials are unsuitable; never pyelonephritis, prostatitis or systemic infection · By mouth
Care settingVeterinarian-directed home treatment after urinalysis and culture, with exact-weight dosing every 8 hours, renal review and early clinical reassessment.
vetman score 4.3/10 Weak evidence support
Evidence confidence: Low Georgia: Expired · № რ-033307 · Verified on 22 Oct 2026 Off-label use

A weak-to-poor feline reserve presentation. Consensus and isolate data suggest urinary activity, but direct feline efficacy is sparse, polyneuropathy has now been reported, renal function is critical and these 50/100 mg whole-tablet units cannot deliver a typical cat dose accurately.

Regulatory and scientific credibility6.5/10

This exact Olainfarm/Olpha 100 mg plain tablet has a current Lithuanian national authorisation, regulator-hosted 2024 product documents and current manufacturer information. It is a human presentation with no dog or cat authorisation; the catalogue market rows incorrectly report no EU/EEA registration and a current Georgian status despite an expired Georgian record.

Clinical efficacy4.5/10

ISCAID includes the same 4.4-5 mg/kg every-8-hour reserve regimen for dogs and cats, and canine/feline isolate MICs support potential urinary activity. Direct feline PK and controlled clinical-outcome evidence are essentially absent, bacterial cystitis is uncommon in younger cats and this exact human tablet has no feline formulation evidence.

Safety and tolerability3.5/10

A 2025 cat developed presumptive peripheral polyneuropathy after 4 mg/kg every 8 hours, improving after withdrawal; the case also had impaired renal indicators. Alongside gastrointestinal, hepatic, pulmonary and hypersensitivity risks, sparse feline safety data and renal dependence make the margin materially uncertain.

Clinical practicality1.5/10

A typical 4 kg cat requires about 17.6-20 mg per dose, far below one 100 mg tablet. The exact plain tablet has no validated equal subdivision or crushing method, and forcing an inaccurate fraction every 8 hours is unacceptable; use an appropriate compounded or alternative presentation if treatment is justified.

Full-course cost-effectiveness-

Current comparable full-course local prices were not verified.

Important safety and use flags

  • Confirm bacterial cystitis before treatment. Culture and susceptibility are required in cats and strongly preferred in dogs; most feline lower urinary signs are not bacterial, and asymptomatic bacteriuria usually should not be treated.
  • Reserve nitrofurantoin for a susceptible lower urinary isolate when preferred veterinary-authorised options are unsuitable. Do not use it as routine empirical therapy or merely because a urine dipstick is abnormal.
  • LOWER URINARY TRACT ONLY. Do not use for pyelonephritis, prostatitis, fever/systemic infection or another tissue infection: therapeutic concentrations are achieved in urine, not renal parenchyma, prostate, blood or other tissues.
  • Do not use with impaired renal function or inadequate urine production. Reduced excretion can lower urinary efficacy while increasing systemic accumulation and polyneuropathy risk; assess creatinine, hydration and urine output before dosing.
  • Stop promptly and reassess for weakness, crouched gait, reduced reflexes, ataxia, tremor, confusion or another neurologic change. Peripheral polyneuropathy can be serious and has been reported in a cat at a conventional q8h regimen.
  • Give with food and water and monitor for nausea, vomiting, diarrhoea or anorexia. Stop and investigate persistent gastrointestinal signs, jaundice/hepatopathy, respiratory signs, fever, rash, facial swelling or another hypersensitivity reaction.
  • Safety in pregnancy, lactation, breeding animals and very young patients is not adequately established for these exact human presentations. Do not assume human paediatric use proves veterinary reproductive or neonatal safety.
  • Review the complete medication list. Antacids containing magnesium, urinary alkalinisers and agents that inhibit tubular secretion can reduce urinary activity or increase toxicity; avoid unreviewed combination with fluoroquinolones because antagonism is described in exact human instructions.
  • Dose from exact body weight and the prescribed 4.4-5 mg/kg every-8-hour regimen; do not substitute a once-daily prophylaxis protocol for active infection. Missed q8h doses and poor adherence can materially compromise this short-half-life urinary drug.
  • Use only a validated dose unit. These exact 50 mg and 100 mg plain tablets have no documented equal-dose score or validated crushing/powder-division method; do not estimate small fractions by eye. Use an appropriate strength or compounded preparation when the intact tablet cannot match the calculated dose.
Assessment sources
  1. VVKT Furadonins 100 mg2024
  2. Olainfarm Furadonin 100 mg2026
  3. Irbit Furadonin 50 mg2026
  4. Georgia Furadonin register2026
  5. ISCAID urinary guideline 20192019
  6. MSD Vet Manual 20252025
  7. Canine q8h urine study2023
  8. Canine recurrent-UTI series2023
  9. Canine/feline isolate study2011
  10. Feline polyneuropathy case2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Nitrofurantoin100 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Olainfarm · Latvia
Registration
Georgia Expired
Human (Ministry of Health, RAMA)
In the register: ფურადონინი 100 მგ, ტაბლეტი
№ რ-033307
Verified on: 22 Oct 2026
 EU Yes, human
№ LT/1/97/3120/001
Verified on: 22 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗